Pfizer (PFE) DIvidends Date & History

Key Takeaways

• Pfizer pays a quarterly dividend of $0.43 per share, or $1.72 annually, with a dividend yield near 6.5%.
• The company has paid dividends for more than 340 consecutive quarters and has raised its payout annually for over 15 years.
• Recent dividend increases have been modest, with a roughly 2.4% bump from $0.42 to $0.43 per share.
• The payout ratio has climbed above 100% on reported earnings, raising questions about dividend sustainability.
• The stock may appeal to income-focused investors, but the elevated yield and payout ratio warrant careful evaluation.

Dividend Overview

Pfizer Inc. (PFE) is one of the world's largest pharmaceutical companies, and its dividend has long been a central feature of its appeal to investors. The company pays a quarterly dividend of $0.43 per share, which translates to an annual payout of $1.72 per share. At recent share prices, this produces a dividend yield in the range of 6% to 6.5%, which is well above the broader market average and among the highest in the healthcare sector.

Pfizer is best characterized as a high-yield dividend stock rather than a fast-growing dividend stock. While the company has a lengthy track record of uninterrupted payments, its recent dividend increases have been minimal. For income-oriented investors, however, the combination of a large, established business and a substantial cash payout makes the stock a notable candidate within the dividend landscape.

Dividend History and Growth

Pfizer's dividend history is one of remarkable consistency. The company has paid a dividend for more than 340 consecutive quarters, a streak spanning over eight decades. It has also increased its dividend annually for more than 15 years, reinforcing its reputation as a dependable dividend payer.

That said, the pace of growth has slowed considerably. The most recent increase lifted the quarterly payout from $0.42 to $0.43 per share, an increase of roughly 2.4%. This modest growth reflects a broader strategic reality: following the sharp revenue surge tied to COVID-19 products and a subsequent normalization, Pfizer has prioritized financial flexibility over aggressive dividend hikes. The company has not cut its dividend, but investors should expect incremental, low-single-digit increases rather than the rapid growth seen at some other large-cap names.

Dividend Sustainability and Payout Ratio

The most important question for dividend investors is whether Pfizer's payout is sustainable, and this is where the analysis becomes more nuanced. On a reported, or GAAP (Generally Accepted Accounting Principles), basis, Pfizer's payout ratio has exceeded 100% in recent periods. This means the company paid out more in dividends than it reported in earnings, driven in part by large non-cash impairment charges.

On an adjusted basis, the picture is more reassuring. Management has guided to adjusted earnings per share (EPS) in the range of $2.90 to $3.10, which would place the dividend payout at a more comfortable level. Still, Pfizer has at times paid out more in dividends than it generated in free cash flow, and the company carries a substantial debt load following several large acquisitions. These factors introduce a degree of risk. The dividend is not in imminent danger of a cut, but its coverage is thinner than the company's long history might suggest, and future increases are likely to remain modest.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical sector, Pfizer's dividend yield stands out as one of the highest. Its yield of roughly 6% to 6.5% compares favorably to peers such as JNJ (Johnson & Johnson), MRK (Merck), and ABBV (AbbVie), which generally offer yields in the low-to-mid single digits. On a yield basis, Pfizer is clearly an outlier at the high end of the group.

However, that elevated yield also signals that the market perceives greater risk. Pfizer's higher yield partly reflects a share price that has declined meaningfully over the past several years and concerns about growth as COVID-related revenue fades. In terms of dividend growth, Pfizer's low-single-digit increases lag some peers that have demonstrated faster payout growth. In short, Pfizer offers superior current income but a comparatively weaker growth profile.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify dividend stocks, income-focused investments, trending names, breakout candidates, and emerging market opportunities far more efficiently than manual screening. If you are looking to build or refine a dividend-focused portfolio, explore the AI Screener to uncover ideas that match your criteria.

Is This Stock Attractive for Dividend Investors?

Pfizer's appeal depends heavily on an investor's goals. For income-focused investors seeking a high current yield, the stock offers an attractive payout that far exceeds what most fixed-income alternatives and the broader equity market provide. The company's long history of uninterrupted payments also lends a degree of comfort to conservative, long-term holders.

For dividend growth investors, however, Pfizer is a more qualified fit. The company's recent increases have been minimal, and its elevated payout ratio limits room for aggressive future growth. Investors who prioritize steadily compounding dividend income over time may find better growth prospects elsewhere, even if those alternatives carry lower current yields.

Ultimately, Pfizer functions as a high-yield, modest-growth dividend stock. It may suit investors who value dependable current income and can accept slower dividend growth and the risks posed by a payout ratio that has, at times, exceeded earnings. As always, individual suitability depends on personal financial circumstances and objectives.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations